Director buying at NervGen Pharma (NGEN)

Director buying at NervGen Pharma (V:NGEN)

Brian Eric Bayley, a Director, acquired 100,000 Common Shares on a direct ownership basis at a price of $1.250 through a private transaction on May 20th, 2020. The insider also acquired 100,000 Warrants with an exercise price of $1.600 until May 20, 2022. This represents a $125,000 investment into the company's shares and an account share holdings change of 40.0%.

NervGen Pharma is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

NervGen Pharma Corp. is a Canada-based biotechnology company. The Company is focused on developing solutions for the treatment of nerve damage and neurodegenerative diseases. The Company is also developing drugs for the treatment of spinal cord injury (SCI), multiple sclerosis (MS) and Alzheimer's disease. Its platform technology targets protein tyrosine phosphatase sigma (PTP sigma), a neural receptor that impedes nerve repair. The PTP sigma receptor promote regeneration of damaged nerves, increase plasticity and stimulate remyelination in animal models. The Company's lead product is NVG-291 referred to intracellular signaling peptide (ISP), treatment for SCI and MS.